Robert Slack

VP and Head of Pharmacology

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Robert Slack is the Vice President and Head of Pharmacology at Galecto Biotech, located in the United Kingdom. His research primarily focuses on the pharmacokinetics and safety of galectin inhibitors, with recent publications exploring their effects on immune response, fibrotic diseases, and COVID-19. Dr. Slack's expertise includes the development and optimization of small molecule inhibitors and their implications in clinical settings.

Articles (12)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (5)

Tao Pun

GlaxoSmithKline Plc

UNITED KINGDOM

View details

Brian McHugh

University of Edinburgh

UNITED KINGDOM

View details

Hakon Leffler

Associate Professor - Professor

Lund University

SWEDEN

View details

Vassilios Aslanis

Head of Clinical Pharmacology

DENMARK

View details

R. Gisli Jenkins

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Robert Slack

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1)

A Quantitative Human Red Blood Cell Agglutination Assay for Characterisation of Galectin Inhibitors

Determining the Affinity and Kinetics of Small Molecule Inhibitors of Galectin-1 Using Surface Plasmon Resonance

Galectin-1 Induces the Production of Immune-Suppressive Cytokines in Human and Mouse T Cells

Single‑Dose Pharmacokinetics and Safety of the Oral Galectin‑3 Inhibitor, Selvigaltin (GB1211), in Participants with Hepatic Impairment

Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants

Galectin-3 inhibitor GB0139 protects against acute lung injury by inhibiting neutrophil recruitment and activation

Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease

Emerging therapeutic opportunities for integrin inhibitors

An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis (DEFINE): A Phase Ib/IIa Randomised Controlled Trial

Pharmacological characterisation of GSK3335103, an oral αvβ6 integrin small molecule RGD-mimetic inhibitor for the treatment of fibrotic disease.

Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis.

Collaborators (5)

Tao Pun

Brian McHugh

Hakon Leffler

Vassilios Aslanis

R. Gisli Jenkins

Make your next move.